Biodesix (NASDAQ:BDSX) Director Acquires $328,937.00 in Stock

Biodesix, Inc. (NASDAQ:BDSX) Director Jack Schuler bought 13,700 shares of the stock in a transaction on Tuesday, August 11th. The shares were bought at an average price of $24.01 per share, for a total transaction of $328,937.00. Following the acquisition, the director owned 540,810 shares in the company, valued at $12,984,848.10. The trade was a 2.60% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Biodesix Stock Performance

NASDAQ BDSX opened at $24.00 on Friday. Biodesix, Inc. has a fifty-two week low of $5.26 and a fifty-two week high of $25.52. The stock has a market cap of $253.20 million, a price-to-earnings ratio of -7.57 and a beta of 0.56. The business has a fifty day moving average of $20.50 and a 200-day moving average of $16.19. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 5.12.

Biodesix (NASDAQ:BDSX) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.90) by $0.19. The business had revenue of $26.86 million for the quarter, compared to the consensus estimate of $26.03 million. Biodesix had a negative return on equity of 788.19% and a negative net margin of 26.97%. As a group, analysts predict that Biodesix, Inc. will post -2.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BDSX has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $27.00 target price (up from $26.00) on shares of Biodesix in a report on Thursday, August 6th. Canaccord Genuity Group lifted their price target on shares of Biodesix from $27.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, August 10th. Weiss Ratings raised shares of Biodesix from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, June 12th. Finally, Roth Capital began coverage on shares of Biodesix in a research note on Wednesday, June 24th. They set a “buy” rating and a $32.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Biodesix presently has a consensus rating of “Moderate Buy” and a consensus target price of $31.33.

Institutional Investors Weigh In On Biodesix

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. AIGH Capital Management LLC acquired a new position in Biodesix in the first quarter valued at $10,996,000. Stempoint Capital LP purchased a new position in Biodesix during the first quarter worth about $1,015,000. Sei Investments Co. acquired a new stake in Biodesix in the 1st quarter worth about $624,000. BlackRock Inc. acquired a new stake in Biodesix in the 2nd quarter worth about $970,000. Finally, Allworth Financial LP purchased a new stake in Biodesix in the 2nd quarter valued at about $112,000. Hedge funds and other institutional investors own 20.96% of the company’s stock.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.